News Details - novonordisk.com
2 days ago · Novo Nordisk Media: Ambre James-Brown +45 3079 9289 [email protected]: Liz Skrbkova (US) +1 609 917 0632 [email protected]: Novo Nordisk investors: Jacob Martin Wiborg Rode +45 3075 5956 [email protected]: David Heiberg Landsted +45 3077 6915 [email protected]: Sina Meyer +45 3075 6656 [email protected]: Ida …
Ozempic maker Novo Nordisk, after trial disappointment, …
1 day ago · Novo Nordisk said an agreement reached last year with privately held Lexington, Mass. company Valo Health that initially was valued at up to $2.7 billion is now been expanded to a $4.6 billion deal.
Novo Nordisk Seeks to Strengthen Obesity Pipeline With Two
1 day ago · On Wednesday, Novo Nordisk A/S NVO and Valo Health, Inc. entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease.
Novo Nordisk Stock Rises as UBS Upgrades Ozempic Maker
1 day ago · Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock to "buy" from "neutral," calling the recent sell-off of the stock ...
Novo Nordisk’s next-generation weight-loss drug CagriSema
Dec 20, 2024 · Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in...
Latest news - Novo Nordisk
Dec 15, 2024 · We plan to invest 2.9 billion Danish kroner to establish a cutting-edge quality control laboratory in Hillerød, Denmark. Environmental challenges have never been more critical or more urgent than they are today. But at Novo Nordisk, we never allow complexity to become a barrier to change.
Compounded semaglutide associated with at least 10 deaths, Novo Nordisk …
Nov 6, 2024 · Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have been associated with at least 100 hospitalizations and 10 deaths, the chief...
Company announcements & press releases - Novo Nordisk
Product-related press releases will only be available upon request after three weeks of publication on our website in order to comply with applicable regulation.
Novo Nordisk Sinks on Disappointing Trial Results for
Dec 20, 2024 · Novo Nordisk's (NVO) U.S.-listed shares sank over 19% in premarket trading Friday after releasing trial results for its next generation of weight loss drug, meant to add to its current lineup of...
Novo Nordisk, Valo Health Expand Drug Discovery and
1 day ago · Novo Nordisk expanded a deal with Valo Health to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using human data and artificial intelligence. The deal ...